Fundraising Fox
Vascular Perfusion Solutions
San Antonio, US · Founded 2016 · Delaware corporation
Find your way into Vascular Perfusion Solutions
Sign up to see every warm intro you have to Vascular Perfusion Solutions
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vascular Perfusion Solutions team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vascular Perfusion Solutions develops the VP.S ENCORE, a portable cardiac perfusion system using a blood-free perfusate to extend donor heart viability up to 8 hours for transplant recovery teams. The investigational medical device is in preclinical evaluation under FDA Breakthrough Device Designation.
Founders & leadership
Vascular Perfusion Solutions was founded in 2016 by Rafael Veraza and Leonid Bunegin.
RV
Rafael VerazaCo-founder · Chief Executive Officer & PresidentRafael Veraza holds a PhD and MPH and has worked in medical device and biotech ventures. He became CEO and President of Vascular Perfusion Solutions in 2022, overseeing development of a cardiac perfusion system that received FDA Breakthrough Device Designation.
LB
Leonid BuneginCo-Founder and Chief Innovation OfficerHe spent more than four decades at UT Health San Antonio as a tenured associate professor in the School of Medicine and later the Graduate School of Biomedical Sciences, following early work as a research assistant professor in the Division of Neurosurgery at the University of Pittsburgh. He co-founded the company in 2022 and serves as its Chief Innovation Officer.
CT
C. Thomas MayesExecutive
TH
Toni HaenninenExecutive
KA
Kristina AndrijauskaiteChief Scientific & Technology OfficerKristina Andrijauskaite is Chief Scientific & Technology Officer at Vascular Perfusion Solutions, where she leads development of oxygenated machine perfusion platforms for organ preservation. She has approximately 20 years of multidisciplinary research experience in organ preservation, oncology, and space biology, including work as a lead scientist on suborbital space missions and selection as an astronaut candidate by the European Space Agency.
MM
Mark MullerNamed on SEC filing
KW
Klaus WeiswurmNamed on SEC filing
Board
CJ
Celia JairalaBoard director
Funding
SEC filings, press & company announcements$154.9M disclosed across 8 of 9 rounds · 2019–2025
- Undisclosed amountSeed FundingAug 2024Source ↗
▶$147MraisedMay 2025 · 21 investors · BiotechnologyRule 506(b)
▶$147MraisedMay 2025 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- C. Thomas MayesExecutive Officer, Director
- Rafael VerazaExecutive Officer, Director
- Toni HaenninenExecutive Officer
- Celia JairalaDirector
- Leon BuneginExecutive Officer, Director
- Kristina AndrijauskaiteExecutive Officer
- Offering amount
- $343.8M
- Amount sold
- $147M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJun 2023 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedJun 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rafael VerazaExecutive Officer, Director
- Paul PerryExecutive Officer
- Klaus WeiswurmDirector
- Tom DeBrookeExecutive Officer, Director
- Leon BuneginDirector
- Mark MullerDirector
- Celia JairalaDirector
- Offering amount
- $2.5M
- Amount sold
- $500K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedMay 2022 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedMay 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Klaus WeiswurmDirector
- Mark MullerExecutive Officer, Director
- Tom DeBrookeExecutive Officer, Director
- Celia JairalaDirector
- Leon BuneginDirector
- Paul PerryExecutive Officer
- Offering amount
- $5M
- Amount sold
- $500K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$850KraisedNov 2021 · 2 investors · BiotechnologyRule 506(b)
▶$850KraisedNov 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leon BuneginExecutive Officer, Director
- Mark MullerExecutive Officer, Director
- Klaus WeiswurmDirector
- Tom DeBrookeExecutive Officer, Director
- Celia JairalaDirector
- Paul PerryExecutive Officer
- Offering amount
- $3M
- Amount sold
- $850K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1.1MraisedAug 2021 · 3 investors · BiotechnologyRule 506(b)
▶$1.1MraisedAug 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leon BuneginExecutive Officer, Director
- Celia JairalaDirector
- Paul PerryExecutive Officer
- Tom DeBrookeExecutive Officer, Director
- Mark MullerExecutive Officer, Director
- Klaus WeiswurmDirector
- Offering amount
- $3M
- Amount sold
- $1.1M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$2.4MraisedAug 2020 · 6 investors · BiotechnologyRule 506(b)
▶$2.4MraisedAug 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tom DeBrookeExecutive Officer, Director
- Paul PerryExecutive Officer
- Leon BuneginDirector
- Celia JairalaDirector
- Mark MullerExecutive Officer, Director
- Klaus WeiswurmDirector
- Offering amount
- $2.5M
- Amount sold
- $2.4M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$602.4KraisedOct 2019 · 13 investors · BiotechnologyRule 506(b)
▶$602.4KraisedOct 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tom DeBrookeExecutive Officer, Director
- Leon BuneginDirector
- Mark MullerExecutive Officer, Director
- Klaus WeiswurmDirector
- Paul PerryExecutive Officer
- Celia JairalaDirector
- Offering amount
- $1.5M
- Amount sold
- $602.4K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$2MraisedJun 2019 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedJun 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leon BuneginDirector
- Mark MullerDirector
- Klaus WeiswurmDirector
- Tom DeBrookeExecutive Officer, Director
- Celia JairalaDirector
- Offering amount
- $8M
- Amount sold
- $2M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Paragonix TechnologiesParagonix Technologies develops, manufactures, and services organ preservation devices that combine cooling techniques with digital tracking and monitoring for clinicians managing donor organs during transplantation. It also maintains the GUARDIAN clinical registries, a database of organ preservation and post-transplant outcome data, serving the organ transplant industry.
Organ RecoveryOrgan Recovery Systems develops organ preservation products and services, including machine perfusion technology for donor kidneys, for transplant programs and transplant professionals. The company supports over 400 transplant programs across 49 countries and also provides clinical and technical support services.
Companies working in the same space as Vascular Perfusion Solutions.
Frequently asked questions
- What does Vascular Perfusion Solutions do?
- Vascular Perfusion Solutions develops the VP.S ENCORE, a portable cardiac perfusion system using a blood-free perfusate to extend donor heart viability up to 8 hours for transplant recovery teams. The investigational medical device is in preclinical evaluation under FDA Breakthrough Device Designation.
- Who founded Vascular Perfusion Solutions?
- Vascular Perfusion Solutions was founded by Rafael Veraza, Leonid Bunegin in 2016.
- How much funding has Vascular Perfusion Solutions raised?
- Vascular Perfusion Solutions has disclosed $154.9M raised across 8 of its 9 known rounds.
- Where is Vascular Perfusion Solutions headquartered?
- Vascular Perfusion Solutions is headquartered in San Antonio, US.